Jefferies hikes its price target on Aegerion (AEGR +2.6%) to $82 from $50 following the...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Jefferies hikes its price target on Aegerion (AEGR +2.6%) to $82 from $50 following the company's presentation at Jefferies Global Healthcare Conference (webcast). Analyst Eun Yang cites "accelerating Rx, lower-than-expected discontinuations to date, [and] likely favorable EU pricing upon unanimous recommendation" of LOJUXTA (I, II), which slide 22 of the presentation shows providing a "meaningful revenue contribution" in FY14.